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Helicobacter pylori are Gram-negative, spiral, 
flagellate bacilli that cause acute and chronic 
gastritis and peptic ulcer disease in both children 
and adults. [1] H. pylori was first isolated in 1983 by 
Warren and Marshal.[2] This discovery was a major 
breakthrough in the management of dyspepsia.[3] The organism has 
also been recognised as a class 1 gastric carcinogen and infection at 
a younger age is thought to increase the risk of developing gastric 
cancer.[4] Children are infected with H. pylori at a much younger age 
in developing countries, some of which report higher rates of gastric 
cancer.[5]
The prevalence of H. pylori infection varies from 20% to 50% 
in industrialised countries,[6] while studies have shown that the 
prevalence is high in regions of Africa and Asia. Therapy can be 
complicated by various factors including drug costs and availability, 
treatment side-effects, and the presence of bacterial strains that are 
antibiotic resistant.[7] 
Antibiotic resistance is an ever-increasing problem in the treatment 
of most microbial infections including H. pylori. The widespread and 
sometimes indiscriminate use of antibiotics in developing countries 
has resulted in a higher prevalence of resistance than in industrialised 
countries.[8] New antimicrobial agents are being developed to 
overcome the problem of antibiotic resistance in bacterial pathogens, 
such as a combination of antibiotics with plant extract and other 
natural products that possess antimicrobial activity.[9] The standard 
and most recommended treatment for the eradication of H. pylori, 
in all international guidelines, is triple therapy using a combination 
of two antibiotics (clarithromycin plus amoxicillin or metronidazole) 
and a proton pump inhibitor (PPI) for at least 7 days.[10] However, 
a recent meta-analysis that included over 53  000 patients showed 
that the eradication rate after a standard triple treatment is currently 
below 80%.[11] Thus eradication is not achieved in at least 1/5 patients, 
prompting research on sequential therapy.
A novel 10-day sequential treatment regimen comprising a PPI 
and amoxicillin double therapy for 5 days followed by a PPI, 
clarithromycin and tinidazole triple therapy for a further 5 days has 
been shown to achieve H. pylori eradication rates of 95% and 97% in 
European adults and children, respectively. This regimen, compared 
with the conventional triple therapy, improved eradication rates by 
18% and 22%, respectively, was well tolerated, safe and had good 
compliance in both adults and children.[12,13] 
Local data on eradication rates are not available but anecdotal 
evidence suggests that there are increasing failure rates to the 
standard triple therapy regimens. 
Objective
To establish whether there was any difference in the treatment of 
H. pylori infection using the 10-day sequential therapy v. the 10-day 
conventional triple therapy, based on clinical improvement of the 
patients and H. pylori eradication.
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Background. Once the diagnosis of Helicobacter pylori is confirmed, treatment requires at least two antibiotics and an acid inhibitor for 
a minimum of seven days. Unfortunately, treatment failures are being frequently reported. Treatment regimens that include sequential 
administration of antibiotics with acid inhibitors have been developed to try and increase the rate of eradication.
Objective. To determine the effectiveness of a novel 10-day sequential therapy compared with the standard 10-day triple therapy for 
treatment of H. pylori infection in children. 
Methods. A double-blinded, randomised, controlled trial was conducted. Children under the age of 16 years with recurrent abdominal 
pain associated with dyspepsia and diagnosed with H. pylori by histology were randomly allocated either to a 10-day sequential treatment 
regimen or to a 10-day conventional triple therapy. Analysis of the outcome of this study was based on clinical improvement and confirmed 
H. pylori eradication based on stool H. pylori antigen detection and/or repeat endoscopy. 
Results. Of the 71 patients included in the analysis, 45 (63.4%) were given the 10-day conventional treatment while 26 (36.6%) received the 
10-day sequential treatment. There was no difference in clinical improvement after treatment in the two therapies. However, there was a 
significant difference in the eradication of H. pylori between the conventional v. sequential regimens (48.8% v. 84.6%, respectively; p=0.02, 
odds ratio 0.19). 
Conclusion. The sequential treatment had a significantly higher H. pylori eradication rate than the conventional treatment.
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Methods
Study design
A double-blinded, randomised, controlled 
trial was conducted on children under the 
age of 16 years. 
Study setting and participants
The study was carried out at the Paediatric 
Gastroenterology Clinic, Aga Khan 
University Hospital, Kenya between March 
2007 and October 2007. Children under the 
age of 16 years presenting with recurrent 
abdominal pain (defined as abdominal pain 
present for at least three months) associated 
with dyspepsia (pain or discomfort in the 
upper abdomen) and diagnosed with H. 
pylori by histology were recruited from 
the clinic on a consecutive basis. Children 
previously treated for H. pylori infection, 
those who had taken any antibiotic, PPI or 
H2 receptor antagonist 4 weeks prior to the 
study, and children with known allergies to 
antibiotics, were excluded.
Permission for this study was granted by 
the Aga Khan University Hospital Research 
and Ethics Committee. Informed consent 
was obtained from the patients or caregivers 
prior to recruitment. All interviews were 
carried out in private and all records were 
accessible only to the investigators.
Data collection
An upper endoscopy was done on all 
children with recurrent abdominal pain 
and dyspepsia using the standard paediatric 
gastroscope under deep sedation with 
propofol administered by an anaesthetist, and 
the endoscopy findings were documented. 
Two biopsy specimens each from gastric 
antrum and body were obtained and placed 
in 10% buffered formalin for histopathology. 
All sections were Giemsa stained to detect 
H.  pylori. Inflammation, activity and other 
mucosal alterations such as gland atrophy and 
intestinal metaplasia were evaluated semi-
quantitatively, based on the Sidney system, by 
the study histopathologist. Patients returned 
to the clinic a week after the endoscopy 
examination. Those with a positive H. pylori 
test on histology were recruited consecutively 
and a structured questionnaire was 
administered to obtain detailed information 
on their clinical symptoms. Participants were 
then referred to the pharmacy where an 
independent pharmacist randomised patients 
to either the 10-day sequential treatment 
or the 10-day conventional treatment. A 
computer programme was used to generate 
random numbers to assign patients to either 
of the two arms as they were recruited. Both 
the study physicians and the patients were 
therefore blinded. A total of 104 patients 
were recruited with 52 receiving sequential 
treatment while 52 were allocated to the 
standard triple therapy arm (Fig. 1).
The 10-day sequential therapy included 
1 mg/kg/day omeprazole plus 50 mg/ kg/ day 
amoxicillin for 5 days followed by 
1 mg/ kg/ day omeprazole plus 15 mg/kg/day 
clarithromycin plus 20 mg/kg/day tinidazole 
for the next 5 days. The 10-day conventional 
triple therapy consisted of 1 mg/kg/day 
omeprazole plus 50  mg/kg/day amoxicillin 
plus 15 mg/kg/day clarithromycin for 10 days.
Follow-up
The patients were asked to return at the 
end of the treatment period (two weeks) 
so as to assess compliance and evaluate any 
adverse events. The child’s parents/guardians 
were questioned regarding compliance 
with medication schedules. There were 
no noncompliance issues. After six weeks 
patients were seen as part of routine practice 
to assess possible persistence of symptoms 
and to undergo a follow-up physical 
examination. The outcome of the treatment 
was based on both clinical improvement 
and whether H.  pylori was eradicated. The 
eradication was determined by use of a 
stool antigen test and/or a repeat histology 
obtained at repeat endoscopy.
Statistical analysis
χ2 analysis was performed to assess differences 
in both treatment regimes, with p<0.05 
being considered significant. Frequencies 
for age and sex of the participants were also 
analysed. Analysis was based on both clinical 
improvement and H. pylori eradication.
Results
Equal numbers of patients were initially 
recruited in both arms of treatment. 
Although the majority of patients in the 
sequential v. conventional treatment groups 
(n=41;79% v. n=49;94%, respectively) 
were seen at the six-week follow-up visit, 
only 26 (63%) of those in the sequential 
arm underwent confirmation of H. pylori 
eradication v. 45 (92%) in the conventional 
therapy arm.
A total of 71 children who were followed 
up to the six weeks were included in this 
study. The male to female ratio was 1.15:1. 
The ages of these children varied from 2 
to 16 years with a mean age of 8.9  years 
(standard deviation (SD) ±3.096). Final 
analysis was done on 45 patients (63.4%) 
in the conventional treatment arm and 26 
(36.6%) in the sequential treatment arm 
(Table  1). There were more males than 
females (53.5% and 46.5%, respectively) and 
just more than a third of the patients were 
>8 years of age. In total, 45/71 (63.4%) 
patients received conventional therapy while 
26 (36.6%) were given sequential treatment.
After randomisation, the group that received 
the conventional therapy had a mean age of 9.1 
years (SD ±3.11; standard error (SE) ±0.46). 
The sequential therapy group had a mean age 
of 8.81 years (SD ±3.12; SE ±0.61). The other 
Recruited with upper abdominal 
pain for >3 months, histology 
positive for H. pylori (n=104)
Randomly allocated to 
sequential treatment 
(n=52)
Randomly allocated to 
conventional treatment 
(n=52)
6 week follow-up 
(n=41, 76%)
6 week follow-up 
(n=49, 94%)
Repeat stool antigen or 
histology for H. pylori 
(n=26/41, 63%)
Repeat stool antigen or 
histology for H. pylori 
(n=45/49, 92%)
Fig. 1. Study flow diagram. 
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demographic factors analysed are shown in Table 2. Although the gender 
ratio was similar in the two groups, there were more children in the 
8 - 11-year and fewer children in the 12 - 16-year age categories in the 
sequential group v. the conventional group. 
Clinical improvement was observed in 88.7% of patients after 
treatment, while eight (11.3%) did not show improvement. Forty 
patients (88.9%) in the conventional treatment arm showed clinical 
improvement v. 23 (88.5%) of those in the sequential treatment 
arm. There was no significant difference in clinical improvement 
between the two regimens (p=0.95; odds ratio (OR) 1.04). Neither 
gender (p=0.19) nor age (p=0.79) of the participants was significantly 
associated with clinical improvement (Table 3). Clinical improvement 
(resolution of dyspeptic symptoms) was seen in almost 90% in both 
treatment groups. Neither age nor sex differences were noted in the 
two groups.
Of the 71 patients, H. pylori was eradicated in 84.6% of the 
children who had received the sequential treatment v. 48.8% of those 
on conventional treatment, the difference being highly significant 
(p=0.02) (Table 4).
Sequential therapy resulted in significantly higher eradication 
of H. pylori (84.6%) than conventional therapy (48.8%). Very few 
patients consented to a repeat endoscopy.
Discussion
There is a general consensus that more effective first-line treatment 
regimens for H. pylori are required to bring the eradication rate closer 
to 100%. Standard triple therapy falls well short of this target, even 
when it is administered for 14 days.[14] 
This study assessed both clinical improvement of the patient and 
H. pylori eradication after treatment. There was no difference in 
clinical improvement for both regimens, suggesting that resolution 
of symptoms after treatment did not necessarily mean eradication of 
the organism.
Slightly more than a third of the patients were in the 4 - 
7-year age category, suggesting early acquisition of H. pylori and 
early inflammatory changes. This has been noted in studies from 
developing countries.[2] 
With reference to H. pylori eradication, patients on the 10-day 
sequential therapy arm had a much higher H. pylori eradication rate 
than patients who received conventional treatment (84.6% v. 48.8%, 
respectively). There was a significant difference in eradication of 
H. pylori between the two regimens (p=0.02). Previous studies have 
also shown that sequential therapy achieves better eradication rates 
than 7-day triple therapy. In a study by Zullo et al.,[12] eradication rates 
for the sequential therapy were 92% by intent to treat and 95% per 
protocol. A recent study from Turkey[15] found that the eradication 
rate was higher for sequential therapy (93.7%) than standard therapy 
(46.4%). These findings are similar to the findings in our study. 
However, the eradication rates with sequential therapy in our study 
were still lower. This may be related to the more prevalent misuse 
of antibiotics in developing countries resulting in more resistant 
bacterial strains.[16] The observed low eradication rates on the 
standard therapy regimen in this study, prompts re-evaluation of the 
currently used first-line treatment for H. pylori infection in Kenya.
Table 1. Characteristics of the study population (N=71)
Characteristic n (%)
Gender
Male 38 (53.5)
Female 33 (46.5)
Age (years)
0 - 3 1 (1.4)
4 - 7 26 (36.6)
8 - 11 25 (35.2)
12 - 16 19 (26.8)
Regimen 
Conventional 45 (63.4)
Sequential 26 (36.6)
Table 2. Demographic characteristics of the 
randomised groups
Characteristics
Therapy, n (%)
Conventional (N=45) Sequential (N=26)
Age (years)   
0 - 3 1 (2.2) 0 (0)
4 - 7 17 (37.8) 9 (34.6)
8 - 11 13 (28.9) 12 (46.2)
12 - 16 14 (31.1) 5 (19.2)
Gender   
Male 24 (53.3) 14 (53.8)
Female 21 (46.7) 12 (46.2)
Table 3. Clinical improvement in the participants
Characteristic
Improvement, n
p-valueClinical None
Gender
Male 32 6 0.19
Female 31 2
Age (years)
0 - 3 1 0 0.79
4 - 7 24 2
8 - 11 21 4
12 - 16 17 2
Regimen 
Conventional 40 5 0.95
Sequential 23 3  
Table 4. Eradication of H. pylori in the different treatment arms
Repeat test
Therapy, n/N (%)
p-valueConventional (N=45) Sequential (N=26)
Stool H. pylori antigen negative 22/45 (48.8) 22/26 (84.6) 0.02
Histology negative for H. pylori 2/5 2/3 -
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The superiority of sequential therapy over standard therapy may 
be related to a reduction in bacterial load with the initial phase of 
treatment with amoxicillin, which reduces the chances of developing 
mutations causing metronidazole and clarithromycin resistance. [17] 
A notable finding was resolution of abdominal symptoms in almost 
90% of patients in both treatment arms, despite a much lower 
eradication rate in the conventional treatment group. This may be 
explained by the antacid effect of the PPI causing symptomatic relief 
of dyspepsia. Unfortunately, we could not follow the patients for 
long enough to ascertain if their symptomatic relief was sustained. 
There were more patients in the 12 - 16-year age category in the 
sequential than the conventional group in the final analysis. Whether 
this made a difference in the eradication rates is difficult to predict, 
but it is expected that teenagers would be more likely to complain if 
symptoms persisted.
This study is the first in Kenya to assess the effectiveness of the 
sequential therapy in children in seeking to improve management of 
H. pylori infections. 
Study limitations
A major setback was that not all patients attended their six-week 
review. The study protocol also entailed a repeat endoscopy and/
or stool H.  pylori antigen testing at this six-week visit to assess 
eradication of H.  pylori. Unfortunately, a substantial number of 
parents would not agree to repeat testing, especially endoscopy, as the 
children’s symptoms had improved. After unblinding of the study, it 
was noted that most of those patients who were lost to follow-up were 
patients from the sequential treatment arm. Follow-up telephone 
calls to a few of the parents of these non-attendees confirmed that 
the patient was symptom free and that the parent did not see the 
need for a repeat visit and/or endoscopy. It is difficult to predict why 
more children in the sequential group did not attend the review v. 
the conventional group. It is known that compliance among patients 
who improve is poor compared with those who are still unwell while 
cultural practices may also play a role.[18,19] It is tempting to suggest 
that because the children in the sequential group felt much better 
than their counterparts in the conventional group, they failed to come 
for their follow-up visit.
Based on findings from this study, there is a need to conduct a 
larger randomised, controlled trial in various settings to fully confirm 
our findings. However, we recommend that a sequential therapy 
regimen should replace the standard triple therapy treatment for 
H. pylori infection in children in Kenya. 
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